Mycoplasma genitalium Detected by Transcription-Mediated Amplification Is Associated With Chlamydia trachomatis in Adolescent Women by Huppert, Jill S. et al.
Mycoplasma genitalium Detected by Transcription-Mediated
Amplification Is Associated With Chlamydia trachomatis in
Adolescent Women
Jill S. Huppert, MD, MPH*, Joel E. Mortensen, PhD†, Jennifer L. Reed, MD‡, Jessica A.
Kahn, MD, MPH*, Kimberly D. Rich, MPH§, and Marcia M. Hobbs, PhD§,∥
*Division of Adolescent Medicine, Cincinnati Children’s Hospital Medical Center and the
University of Cincinnati College of Medicine, Cincinnati, Ohio
†Laboratory Medicine, Cincinnati Children’s Hospital Medical Center and the University of
Cincinnati College of Medicine, Cincinnati, Ohio
‡Emergency Medicine, Cincinnati Children’s Hospital Medical Center and the University of
Cincinnati College of Medicine, Cincinnati, Ohio
§Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
∥Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North
Carolina
Abstract
Objectives—The clinical significance of Mycoplasma genitalium (MG) infection in adolescent
women is poorly understood. We compared the prevalence of MG with that of other sexually
transmitted organisms such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and
Trichomonas vaginalis (TV) and assessed the associations of MG with sexual behaviors,
genitourinary symptoms, physical and laboratory findings.
Study Design—Women aged 14 to 21 years (n = 331) were recruited from an urban medical
center. The subjects’ sexual behaviors, genitourinary symptoms, and physical findings were
recorded. Endocervical swabs were collected for CT and NG testing and vaginal swabs for wet
mount, Gram stain, TV and MG testing. MG infection was identified by nucleic acid amplification
using a transcription-mediated amplification assay.
Results—MG was detected in 74 (22.4%), CT in 79 (24.4%), TV in 60 (18.2%), and NG in 35
(10.7%) subjects. MG infection was not associated with vaginal symptoms, physical evidence of
cervicitis, or findings on wet mount or Gram stain. In logistic regression, variables positively
associated with MG were current CT [odds ratio (OR), 2.3; 95% confidence interval (CI), 1.4–4.4]
and recent sexual contact (≤7 days) (OR, 2.0; CI, 1.1–3.2). Dysuria (OR, 0.44; CI, 0.2– 0.96) and
use of hormonal contraception (OR, 0.55; CI, 0.3–1.0) were negatively associated with MG
infection.
Conclusion—In adolescent women, MG infection was as common as chlamydial infection and
trichomoniasis and more common than gonorrhea. MG was associated with CT and recent sexual
contact but not with vaginal symptoms or signs of cervicitis.
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ADOLESCENT WOMEN FREQUENTLY COMPLAIN of genitourinary symptoms and
are at high risk for sexually transmitted infections (STI) with organisms such as Chlamydia
trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV). However,
clinicians often cannot establish a definitive diagnosis for vaginitis or cervicitis.1 In
addition, symptoms sometimes persist despite treatment. Infection with a sexually
transmitted organism that is difficult to culture, such as Mycoplasma genitalium (MG), may
explain genitourinary symptoms or poor response to treatment of other STI. Yet, little is
known about the prevalence or significance of MG in adolescent women who are at high
risk for STI.
MG has been identified as an etiologic agent of urethritis in men.2 However, in women, the
results from studies that examined the associations between MG and genitourinary
symptoms or signs are inconsistent. In one study using stored specimens that were obtained
in the 1980s from women attending a sexually transmitted disease clinic, the odds of having
mucopurulent cervicitis (MPC) among MG-positive women as detected by polymerase
chain reaction (PCR) were threefold higher than among women without MG.3 In another
study using detailed symptom constructs, MG detected by culture or PCR was associated
with abnormal vaginal discharge but not MPC.4 In other studies, neither clinical signs nor
patient symptoms were associated with MG infection.5,6
Recently, a transcription-mediated research assay (TMA) has been shown to be highly
sensitive and specific for the detection of MG and to perform better on vaginal swabs than
cervical or urine samples.7 The advent of nucleic acid amplification testing provides
opportunities to more accurately determine the prevalence of MG in adolescent women and
to determine whether, in this population, MG is associated with genitourinary symptoms,
signs, or other STI. In addition, it may be important to identify clinical or laboratory
findings that predict which patients may benefit from targeted MG testing, since widespread
screening for MG is unlikely to occur in the near future. If strong associations were found
between MG and other STI, presumptive treatment for MG may even be indicated, echoing
the approach used in the past when, in the absence of sensitive tests for CT, patients with
gonorrhea were treated presumptively for chlamydial infections.
The objectives of the current study were to describe the prevalence of MG in sexually active
adolescent women at high risk for STI and to explore the associations of MG with sexual
behaviors, genitourinary symptoms, physical and laboratory findings, and other STI.
Subjects, Materials, and Methods
Subjects
Female adolescents aged 14 to 21 years were recruited from an urban, hospital-based Teen
Health Center (THC) or emergency department (ED) between July 2004 and May 2006 to
participate in a cross-sectional STI screening study. The full study has been described
previously.8 Inclusion criteria were a history of heterosexual contact in the last 6 months and
reporting either genitourinary symptoms or a risk for STI (report of >1 sexual partner in the
last 3 months, a new sexual partner in the last 3 months, or inconsistent condom use).
Subjects signed informed consent, and the institutional review board approved the study
with a waiver of the requirement for parental permission for participants < 18 years of age.
Each subject was interviewed confidentially by a trained research assistant. The interviewer
collected demographic variables and assessed self-reported sexual behaviors (condom use,
contraceptive use, number of sexual partners in the last 90 days, date of last sexual
intercourse) and elicited current genitourinary symptoms (vaginal itching or discharge,
dysuria, abnormal bleeding, and pelvic pain) using a structured data-collection instrument. A
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pelvic exam was performed by a trained clinician, and physical findings during the pelvic
exam (abnormal vaginal discharge, mucopurulent cervical discharge, cervical friability,
bleeding, or pelvic tenderness) were recorded on the data collection form. During the
speculum portion of the pelvic exam, the clinician obtained swabs from the endocervix and
the vaginal fornices for laboratory testing.
Laboratory Methods
Endocervical swabs were tested for CT using a strand displacement assay (BD ProbeTec
ET®, Becton Dickinson, Sparks, MD), and for NG using either culture or the strand
displacement assay at the clinician’s discretion.
For subjects recruited from the THC, a complete wet mount evaluation was performed in the
on-site laboratory by an experienced clinician. For subjects recruited from the ED, vaginal
swabs were transported to the clinical laboratory, where a Gram stain was examined. Wet
mount or Gram stain slides were read at 400× magnification to quantitate white blood cells
(WBCs) and the proportion of epithelial cells that were clue cells, which were categorized as
≤10 versus >10 WBCs and ≤20% versus >20% clue cells per field, respectively. Yeast forms
seen on wet mount or Gram stain were considered a positive result for yeast.
After subject recruitment was complete, dry vaginal swabs that had been stored at −80°C
were processed in APTIMA® swab transport medium and were tested for TV and MG using
TMA assays performed on a DTS 400 instrumentation system (Gen- Probe, San Diego, CA).
The TV assay used T. vaginalis analyte specific reagents with the APTIMA® General
Purpose Reagents (GPR) as described previously.8
For MG TMA, 400 µL of processed vaginal swab specimen was tested as previously
described.7 Briefly, oligonucleotides specific for MG 16S rRNA were used for target
capture and amplification using the APTIMA® GPR. Purified MG total nucleic acids and
sterile water were used as positive and negative controls, respectively.
Definitions of Outcomes
Clinical samples for CT and NG were deemed positive if the corresponding tests were
positive. TMA results >30,000 relative light units (RLU) were considered positive for TV.
MG samples with initial results >50,000 RLU were retested from the same processed
specimen, and specimens with repeat results >50,000 RLU were considered positive for
MG. One sample was positive on initial testing but negative on repeat testing and was
classified as negative. All samples with initial results <50,000 RLU were considered
negative for MG.
MPC was defined as the presence of purulent or yellow discharge at the cervical os. Cervical
friability was defined as easy bleeding with application of a swab to the cervix. Clinical
cervicitis was defined when the provider marked either “MPC” or “cervical friability” on the
data collection form. Vaginal symptoms included any chief complaint or elicited patient
report of vaginal itching or discharge. Any genitourinary symptoms were recorded as
present if the interview revealed a patient report of vaginal symptoms, dysuria, abnormal
vaginal bleeding, or pelvic pain. Hormonal contraception included the use of combined oral
contraceptive pills, the contraceptive patch or depot medroxyprogesterone acetate.
Statistical Analyses
Dichotomous variables were compared with MG status using χ2 tests, and continuous
variables were compared using Student t test. Analyses were performed on the full data set
and then repeated on 4 subsets: those without CT, those without any other STI, those
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without vaginal infections (TV or yeast), and those without infections related to cervicitis
(CT and NG).
Because we used 2 methods to ascertain clue cells and WBCs in vaginal fluid (wet mount or
Gram stain), we stratified the sample to see if associations with MG varied by this method.
We found no significant associations between MG and wet mount or Gram stain findings;
therefore, we combined the data for wet mount and Gram stain results.
Logistic regression models were used to determine which variables were independently
associated with MG infection. Variables that demonstrated an association with MG at P <0.1
in the bivarate analyses were included in the multivariable models. Because several risk
behavior variables were highly correlated, the impact of each of these variables was tested
by comparing the full and reduced models using a likelihood ratio test. The most
parsimonious model is presented.
Results
Three hundred sixty-nine subjects were recruited; 331 with samples available for MG testing
comprised the study sample. MG was detected in 74 (22.4%) subjects, CT in 79 (24.4%),
TV in 60 (18.2%), and NG in 35 (10.7%) subjects. The mean age of participants was 17.7
years (range, 14–21); other demographics and subject history are displayed in Table 1.
Those with MG were more likely to report sex in the last 7 days (58.1% vs. 42.8%, P = 0.02)
and >1 sexual partner in the last 3 months (35.2% vs. 23.4%, P = 0.04) than those without
MG. In addition, those with MG were slightly less likely to report using hormonal
contraception at last intercourse (25.7% vs. 37.7%, P = 0.055). Although in this sample,
those age 14 to 17 were more likely to have CT than those 18 to 21 (29.2% vs. 18.0%, P =
0.02), younger age was not associated with MG, NG, or TV.
We evaluated symptoms reported by subjects and signs documented by the provider
individually and in groups and found no differences between those with or without MG
infection (Table 2). Wet mount and Gram stain results also were not associated with MG,
whether analyzed together or separately. There was a trend toward greater dysuria and
uterine/adnexal tenderness in those without MG infection that was not significant in
bivariate analyses.
Adolescent women with MG had higher prevalence of CT, NG, and TV; this difference was
statistically significant only for CT (Table 2). Thus, women with MG were more likely to be
coinfected with CT than women without MG (37.5% vs. 20.0%, P = 0.003). More than half
of young women with MG had another STI, compared with about a-third of those without
MG (P = 0.003). However, no other clinical signs or patient-reported symptoms were
significantly associated with MG infection.
A logistic regression model was developed to assess the independent contribution of
variables associated with MG infection (Table 3). Both current CT infection and recent
sexual intercourse (within the last 7 days) were associated with a twofold increase in the
odds of MG infection. Dysuria and use of hormonal contraception at last sexual contact were
associated with decreased odds of MG infection. A report of multiple partners was not
significant and was dropped from the final model.
We assessed whether an MG infection could explain any patient- reported symptoms or
clinical signs that were not explained by another infection. Thus, we repeated the analyses
on the subsets of subjects that were negative for CT (n = 245), negative for CT and NG (n =
226), negative for all other STI (n = 202), and negative for other vaginal infections (TV and
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yeast) (n = 208). We identified no significant associations between MG status and symptoms
or signs in any of these subsets (data not shown).
In contrast to our findings with MG, clinical cervicitis was associated with CT infection.
Women with cervicitis were more likely to have CT than those without cervicitis (36.9% vs.
19.8%, P = 0.02). NG prevalence did not differ between those with and without cervicitis
(10.7% vs. 9.7%). In the absence of CT infection (n = 235), MG prevalence did not differ
between those with and without cervicitis (15.1% vs. 19.2%, P = 0.5). In those with CT
infection (n = 76) MG prevalence was slightly lower in those with cervicitis compared to
those without (25.8% vs. 40.2%, P = 0.2), but this difference did not reach statistical
significance.
Of note, 44% of women with vaginal symptoms and 58% of those with clinical cervicitis
had no documented infection. It is possible that bacterial vaginosis or other noninfectious
conditions could account for some of these symptoms and signs.
Discussion
In this sample of adolescent women, we documented a high prevalence of MG (22%) that
was comparable to the prevalence of CT (24%) and TV (18%) and was higher than that of
NG. Other studies have reported a similar prevalence of MG in women: 15% in a Seattle
STD clinic (18 –27-year-old women)7; 19% in a Baltimore STD clinic of adult women9; and
16% among 18- to 35-year-old Nairobi sex workers.5 In contrast, the prevalence of MG in
STD clinics in Sweden was 6.3%,10 and up to 4.1% in a longitudinal, nonclinic based
sample of adolescents in Indianapolis. 6
The higher prevalence of MG we report here in adolescent women seeking care is not
surprising, since we purposefully recruited a sample at high risk for all STI. Elicited
genitourinary symptoms were common (any symptom present in 89%) and overlapped
considerably with other risks for STI (shown in Table 1), with 62% reporting a history of
STI, 52% reporting no condom use at last sexual contact, and 26% reporting a new partner
in the last 3 months.
In our sample, there were a large number of women aged 14 to 17 who were at higher risk
for CT than those aged 18 to 21. However, the MG prevalence in these younger women
(21.3%) was similar to that of women aged 18 to 21 (23.7%). One explanation may be that
unlike CT, MG does not have a strong affinity for the immature adolescent cervix.
Regardless of age, young women in our cross-sectional study were frequently coinfected
with MG and CT. Similar results were seen in 2 longitudinal studies. In the cohort of
Nairobi sex workers, incident CT increased the hazard of acquiring MG 2.5-fold, and in
adolescents, the odds of MG in the presence of CT were 1.9.5,6 These results are similar to
our findings. This relationship may have implications for understanding the pathogenicity
and possible treatment options for MG.
In this sample of young women at risk for STI, MG infection was not independently
correlated with higher-risk sexual behaviors such as inconsistent condom use, new partners,
or multiple sexual partners. MG prevalence was greater with shorter interval since last
sexual contact. This may represent spontaneous clearance of infection or exposure to
adequate antibiotic therapy. In a longitudinal study, 70% to 90% of MG infections resolved
within 3 to 7 months without treatment.5 The protective effect of hormonal contraception
that we found may be because of changes in the vaginal ecosystem related to the hormones
themselves. Alternatively, this variable may be a marker for an unmeasured behavior, such
as being in a long-term monogamous relationship, which may decrease the risk of MG.
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We did not identify any clinical findings that were reliably associated with MG infection.
This is disappointing in light of reports that a clinical finding of vaginal leukocyte count
(>10 WBC/high powered field) is predictive of infections with CT, NG, and TV.11,12 In
addition, we were unable to attribute clinical cervicitis to MG infection, even in those
without CT or NG. Results from other studies are conflicting, and may be because of
differences in the populations studied, the methods used for MG detection, or the definitions
used for cervicitis. Three of six recent studies showed an association between MG and
cervicitis.3,10,13 In these 3 studies, the populations were adult STD clinic attendees, many
reported vaginal symptoms, and the prevalence of MG ranged from 6% to 26%. MG was
detected by in-house PCR from cervical samples, some of which had been frozen,3 while
others were performed at the time of evaluation. Cervicitis was variably defined as cervical
mucopus, friability or >30 polymorphonuclear leukocytes/1000× field on Gram stain. In 2
longitudinal studies5,6 and 2 cross-sectional studies4,14 without demonstrated associations
between MG and clinical cervicitis, MG was defined by culture or PCR; cervicitis was
defined as any of 4 clinical signs or the presence of more polymorphonuclear leukocytes
than epithelial cells on a wet smear of vaginal secretions. Given this wide variation in
definitions of both MG infection and clinical cervicitis, it is not surprising that statistical
measures of association are inconsistent.
In our adolescent sample, MG infection was not correlated with signs or symptoms of
vaginitis. This is consistent with findings from a longitudinal study of adolescents by Tosh
et al.6 However, we did not differentiate between chief complaint and elicited symptoms,
and our attempt to standardize recording of symptoms may have encouraged overreporting
in these adolescent women. In addition, both our study and that of Tosh et al. relied upon
patient self-report and did not include the patient’s perception of whether the symptoms
were abnormal or bothersome, as has been described by some authors.15
The negative association with dysuria is perplexing, as others have found no association
between MG and urinary symptoms in adult women.10 Our findings may be related to the
adolescent’s inability to describe her genitourinary symptoms accurately. In light of the
evidence that MG is associated with symptomatic urethritis in studies of men,2,10
asymptomatic infection in women should not be discounted.
This study has the advantage of a large sample of adolescent females and sensitive
laboratory methods to detect infection with the 4 organisms studied: CT, NG, TV, and MG.
The study is limited by the cross-sectional design, which does not allow us to examine
temporal relationships or the risk of consequences, such as pelvic inflammatory disease or
HIV acquisition. Another limitation is that subjects were recruited for their known STI risks;
thus the prevalence in this study sample will likely differ from other populations with lower
risks. Additionally, we relied upon patient reporting of symptoms and clinician reporting of
signs and physical findings. The use of multiple clinicians to assess cervicitis may have
resulted in some misclassification that contributed to our observed lack of association
between MG and cervicitis.
The role of MG as a pathogen should be further explored. It is well accepted that MG is a
sexually transmitted organism that is associated with symptoms of urethritis in men. Have
we fulfilled Koch’s postulates that MG is an etiologic agent for clinical symptoms in
women? Initial, cross-sectional and observational data are conflicting. Animal models
support biologic plausibility for inflammation and tissue damage.16,17 We await treatment
data to show that symptoms or signs that are detected when the organism is present are
shown to resolve after treatment. In addition, longitudinal data using various detection
methods are needed to ascertain whether infection detected by recovery of viable organisms
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is different from colonization or transient positivity by nucleic acid amplification testing
(NAAT).
Conclusions
M. genitalium is a highly prevalent STI in sexually active female adolescents and is strongly
associated with current CT infection. We did not identify any clinical signs or symptoms
that were significantly associated with MG infection. Some indicators such as positive CT
and recent sexual contact may be reasons to obtain MG testing if it is available. The
transcription-mediated amplification assay used in this study is sensitive and reliable but not
widely available, and it may be prohibitively expensive for many clinicians. Accessible
diagnostic methods will facilitate longitudinal studies that can accurately assess the role of
MG as an etiology of genitourinary symptoms or other adverse outcomes such as pelvic
inflammatory disease or acquisition of HIV.
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TABLE 1







Age, 18–21 yr 143 (43.2) 34 (45.9) 109 (42.4) 0.59
Age, 14–7 yr 188 (56.8) 40 (54.1) 148 (57.6)
Black race 272 (82.2) 63 (85.1) 209 (81.3) 0.45
Site of care = emergency department 187 (56.5) 44 (59.5) 143 (55.6) 0.56
Condom used at last sexual contact 159 (48.0) 37 (50.0) 122 (47.5) 0.70
Hormonal contraception used at last sexual contact 116 (35.0) 19 (25.7) 97 (37.7) 0.055
Self report of any prior STI 206 (62.2) 47 (63.5) 159 (61.9) 0.79
>1 sexual partner in last 3 mo 86 (25.9) 26 (35.1) 60 (23.4) 0.04
Recent sexual contact (≤7 d) 153 (46.2) 43 (58.1) 110 (42.8) 0.02
New sexual partner in the last 3 mo 100 (30.2) 21 (28.4) 79 (30.7) 0.69
Low risk (≤1partner in last 3 mo and no new partners) 198 (59.8) 41 (55.4) 157 (61.2) 0.38
Data are displayed as number (column %).
*
P value determined by χ2 tests of significance.
MG indicates M. genitalium; STI = sexually transmitted infection.
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TABLE 2
Subject Symptoms, Signs, and Coinfections Stratified by Presence or Absence of M. genitalium
Total MG Positive MG Negative P*
Symptoms reported by subject N=331 N=74 N=257
Vaginal discharge 175 (51.9) 39 (52.7) 136 (52.9) 0.97
Vaginal itching 107 (32.3) 20 (27.0) 87 (33.8) 0.27
Any vaginal symptoms 211 (63.9) 44 (59.6) 167 (64.9) 0.38
Dysuria 63 (19.0) 9 (12.2) 54 (21.0) 0.09
Abnormal vaginal bleeding 40 (12.1) 9 (12.2) 31 (12.1) 0.9
Pelvic pain 176 (53.2) 42 (56.8) 134 (52.2) 0.48
Any genitourinary symptoms 295 (89) 64 (86.5) 231 (89.9) 0.40
Signs noted by provider† N=318 N=71 N=247
Abnormal vaginal discharge 137 (43.1) 26 (36.6) 111 (44.9) 0.21
Mucopurulent cervicitis 47 (14.8) 7 (9.9) 40 (16.2) 0.18
Friable cervix 52 (16.4) 11 (15.5) 41 (16.6) 0.82
Clinical cervicitis 87 (27.4) 17 (23.9) 70 (28.3) 0.46
Cervical motion tenderness 39 (12.3) 6 (8.4) 33 (13.4) 0.27
Uterine tenderness 22 (6.9) 2 (2.8) 20 (8.1) 0.18‡
Adnexal tenderness 48 (15.1) 7 (9.9) 41 (16.6) 0.16
Any pelvic tenderness 73 (23.0) 12 (16.9) 61 (24.7) 0.17
Clue cells >20% of epithelial cells/HPF§ 70 (23.7) 14 (20.0) 52 (23.1) 0.58
WBC >10 /HPF‖ 66 (22.5) 13 (19.7) 36 (15.9) 0.46
Coinfections (n = 331 unless noted)
Trichomoniasis 60 (18.2) 18 (24.3) 42 (16.4) 0.12
Chlamydia¶ 79 (24.4) 27 (37.5) 52 (20.6) 0.003
Gonorrhea# 35 (10.7) 10 (13.9) 25 (9.8) 0.33
Either chlamydia or gonorrhea** 97 (30.0) 31 (43.6) 66 (26.2) 0.005
Any STI 129 (39.0) 40 (54.0) 89 (34.6) 0.003
Data are displayed as number (%).
*
χ2 test, except as noted.
†




Missing 8 MG+ and 28 MG−, total = 295.
‖
Missing 8 MG+ and 30 MG−, total = 293.
¶
Missing 2 MG+ and 5 MG−, total = 324.
#
Missing 2 MG+ and 3 MG−, total = 326.
**
Missing 3 MG+ and 5 MG−, total = 323.
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MG indicates M. genitalium; WBC = white blood cells seen on vaginal wet mount or gram stain; HPF =high-powered field; STI = sexually
transmitted infection with chlamydia, gonorrhea, or trichomoniasis.
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TABLE 3
Associations of Significant Variables With M. genitalium Infection in Female Adolescents Predicted by





OR 95% CI AOR 95% CI
Chlamydial infection 2.3 1.3–4.1 2.5 1.4–4.4
Recent sexual contact (≤7 d) 1.8 1.1–3.1 2.0 1.1–3.2
Dysuria 0.52 0.24–1.1 0.44 0.20–0.96
Hormonal contraception 0.59 0.33–1.1 0.55 0.3–1.0
>1 partners in last 3 mo 1.8 1.0–3.1
*
Adjusted for all listed variables; the variable “>1 partners in last 3 mo” was highly correlated with hormonal contraception and did not reach
significance in the final model.
OR indicates odds ratio; CI = confidence interval; AOR = adjusted odds ratio.
Sex Transm Dis. Author manuscript; available in PMC 2013 October 25.
